Table 1.
Baseline characteristics of patients
| IVB + PD n=22 |
PD n=10 |
P-value | |
|---|---|---|---|
| Age (years) | 66.9±8.9 | 69.7±8.7 | 0.41* |
| Duration of symptoms (days) | 8.1±3.7 | 6.1±4.9 | 0.23* |
| SMH diameter (DD) | 4.7±2.8 | 4.4±1.7 | 0.72* |
| Location of PCV (eyes) | |||
| Subfoveal/juxtafoveal | 4 (18.2%)/2 (9.1%) | 3 (30%)/0 (0%) | 1.00** |
| Extrafoveal | 16 (72.7%) | 7 (70%) | |
| SF6 volume (mL) | 0.41±0.06 | 0.49±0.06 | <0.001* |
| BCVA (logMAR units) | 0.84±0.36 | 0.94±0.69 | 0.59* |
| CFT (μM) | 561.0±178.4 | 648.4±162.1 | 0.235* |
Notes: Data are presented as the mean ± standard deviation
*
unpaired t-test
**
Fisher’s exact probability test.
Abbreviations: IVB, intravitreal bevacizumab; PD, pneumatic displacement; SMH, submacular hemorrhage; SF6, sulfur hexafluoride; BCVA, best-corrected visual acuity; CFT, central foveal thickness; PCV, photocoagulation.